Interrogating specific cellular activities often entails the dissection of posttranslational modifications or functional redundancy conferred by protein families, which demands more sophisticated research tools than simply eliminating a specific gene product by gene targeting or RNA interference. We have developed a novel methodology that involves engineering a single SCF bTrCP -based ubiquitin ligase that is capable of not only simultaneously targeting the entire family of ErbB receptor tyrosine kinases for ubiquitination and degradation, but also selectively recruiting only activated ErbBs. The engineered SCF bTrCP ubiquitin ligase effectively blocked ErbB signaling and attenuated oncogenicity in breast cancer cells, yet had little effect on the survival and growth of non-cancerous breast epithelial cells. Therefore, engineering ubiquitin ligases offers a simple research tool to dissect the specific traits of tumorigenic protein families, and provides a rapid and feasible means to expand the dimensionality of drug discovery by assessing protein families or posttranslational modifications as potential drug targets.
INTRODUCTION
Normal or oncogenic signaling is often orchestrated by not one, but multiple members of signaling proteins with redundant functions. Efficacy of targeted inhibition of one signaling molecule is frequently compromised as a result of compensatory upregulation of another family member, which accounts in part for the resistance to targeted therapy. Moreover, activation of a given signaling pathway under physiological or pathological conditions further entails posttranslational modifications of signaling molecules, for example, phosphorylation of receptor tyrosine kinases. Such complexities present challenges of inactivating a disease pathway by targeting one signaling protein, yet offer new avenues or strategies for disease intervention by collectively abrogating the entire family of functionally overlapping proteins, or by ablation of a specific posttranslational event that is preferentially dysregulated in a diseased state. However, functional assessments of these new biological space in drug discovery require more sophisticated tools than simple elimination of a given target protein by established methodology, such as RNA interference or gene targeting. In this regard, chemical inhibitors can potentially fulfill the desired functionality, but they are often not available at this early discovery stage, and are developed after a specific drug target is validated. As such, efforts to explore the value of cellular protein families as emerging drug targets are largely hampered by the lack of effective experimental tools in pre-clinical and clinical models.
One example of such cases is the epidermal growth factor receptor (EGFR/ErbB) family, which consists of EGFR (EGFR/HER-1 or ErbB1), ErbB-2 (Neu or HER-2), ErbB3 (HER-3) and ErbB4 (HER-4). It has been established that the ErbB RTKs are frequently hyper-activated in cancers and contribute to tumor survival, growth, progression, angiogenesis and metastasis. [1] [2] [3] [4] [5] [6] [7] Overexpression of ErbB2 is found in nearly 20% of breast cancer patients as well as other malignancies, and is correlated with shorter relapse-free survival and poor prognosis. Individual ErbB RTKs have been intensely pursued as therapeutic targets through the attenuation of their signaling activities. [8] [9] [10] [11] Numerous attempts have been made to inhibit EGFR and ErbB2 signaling, such as inactivating monoclonal antibodies directed against the extracellular domain of the receptors and chemical inhibitors that block intracellular tyrosine kinase activity. Currently, novel therapeutic strategies targeting multiple ErbB RTKs are being intensely pursued as more effective ways to block the ErbB signaling that is often necessary to sustain tumor growth and survival. Moreover, in order to reduce the potential cytotoxicity to normal cells that results from ErbB eradication, it is preferable to selectively target activated, tyrosine-phosphorylated ErbB RTKs instead of knocking out all ErbB expression. However, such specific and multifaceted manipulation of ErbB activity is technically challenging using conventional methods and tools.
Ubiquitin-dependent proteolysis constitutes the major pathway that eukaryotic cells employ to degrade cellular proteins, and involves a cascade of enzymatic reactions catalyzed by the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the E3 ubiquitin ligase. Of these enzymes, the E3 ubiquitin ligase is exclusively responsible for defining substrate specificity through direct binding to the target protein. The multimeric SCF bTrCP ubiquitin ligase, which consists of Skp1, CUL1, the F-boxcontaining bTrCP substrate receptor and the Rbx1/Roc1/Hrt1 adapter, selectively targets a variety of key regulators of the cell cycle, cell signaling and transcription for ubiquitination and degradation. 12 Among the SCF subunits, the F-box protein bTrCP is exclusively responsible for substrate recognition and recruitment. Engineering F-box proteins has been established as a powerful strategy to direct the SCF machinery to target a variety of cellular proteins for degradation in cultured eukaryotic cells and animal models (reviewed in Zhou 13 and references therein). More specifically, the SCF ubiquitination machinery can be harnessed to degrade non-SCF targets by attaching an F-box protein to a peptide or motif that is able to bind to the protein of interest. [13] [14] [15] [16] [17] [18] [19] [20] [21] In this study, we fused the phosphotyrosine-binding (PTB) domain from the Shc signaling protein to the C-terminus of bTrCP to selectively capture all activated (tyrosine-phosphorylated) EGFR/ErbB family proteins and recruit them to the SCF machinery for degradation. Our data demonstrated the efficacy of the engineered F-TrCP-Shc E3 ligase in selectively inducing ubiquitinmediated degradation of all activated ErbB family proteins. We also showed that F-TrCP-Shc suppressed tumor growth through increased apoptosis and G1 arrest, sensitized ErbB2-overexpressing breast cancer cells to cisplatin-mediated killing and inhibited tumorigenicity in nude mice.
RESULTS
The engineered F-TrCP-Shc ubiquitin ligase interacts with ErbB2 and induces its degradation in a dose-dependent manner To specifically recruit activated (oncogenic) ErbB proteins to the SCF ubiquitination machinery, we first engineered a chimeric F-TrCP-Shc ubiquitin ligase with the PTB domain of the Shc adapter protein fused in-frame to the carboxyl terminus of bTrCP and a FLAG tag at the N-terminus (Figure 1a) . The PTB domain of Shc specifically binds to the tyrosine phosphorylated/activated intracellular domain of EGFR (pY1114, pY1086 and pY1148), ErbB2 (pY1248), ErbB3 (pY1328) and ErbB4 (pY1284). [22] [23] [24] [25] In order to verify the specificity of the F-TrCP-Shc/ErbB interaction, we created a phospho-ErbB binding-defective construct, F-TrCP-Shc(m), that possesses the F198V point mutation in the PTB domain but is otherwise identical to F-TrCP-Shc (Figure 1a) . 26 To test the binding of the engineered F-TrCP-Shc ubiquitin ligase to ErbB2, FLAGtagged chimeric constructs were transiently transfected into 293T cells and co-immunoprecipitation experiments were performed. As shown in Figure 1b , F-TrCP-Shc, but not F-TrCP-Shc(m), effectively binds to endogenous ErbB2. To investigate whether F-TrCP-Shc can reduce endogenous ErbB2 levels through ubiquitin-dependent proteolysis, 293T cells were transfected with increasing doses of F-TrCP-Shc or F-TrCP-Shc(m). Indeed, the ectopic expression of F-TrCP-Shc induced robust polyubiquitination and dose-dependent downregulation of endogenous ErbB2, whereas the binding-deficient F-TrCP-Shc(m) did not (Figures 1c-d) .
Ubiquitinated ErbB receptors can be degraded by either the 26S proteasome or trafficked to the lysosomes for destruction. 27, 28 As seen in Figures 1e and f, treatment of F-TrCP-Shc-expressing cells with the proteasome inhibitor MG132 blocked ErbB2 degradation, whereas the lysosomal acidification inhibitor chloroquine had no discernable effect, indicating that the engineered F-TrCP-Shc construct preferentially directs ErbB2 toward proteasomal degradation. Therefore, the PTB domain of Shc, upon fusion to F-TrCP, effectively binds ErbB2 and recruits it to the SCF machinery for ubiquitination and proteasome-dependent degradation.
F-TrCP-Shc promotes degradation of all ErbB family proteins and inhibits ErbB signaling The compensatory increase in the expression levels of other ErbB family members has been reported to contribute to the acquired resistance of breast cancer cells to ErbB2 inhibitory drugs in patients. 29 This finding raises the question of whether the simultaneous attenuation of all ErbB proteins could potentially improve the therapeutic efficacy and outcome in cancer patients with ErbB over-activation. Thus, we selected the Shc PTB domain for fusion with bTrCP, as Shc functions as a mediator of ErbB signaling and interacts with all members of the ErbB family upon RTK activation. F-TrCP-Shc is therefore able to degrade all activated ErbB RTKs, which creates a unique opportunity to examine the physiological consequences of fully attenuated ErbB signaling. Indeed, F-TrCP-Shc, but not F-TrCP-Shc(m), stimulates ubiquitination of EGFR and ErbB3 (Supplementary Figure S1) .
To achieve sustained degradation of ErbB RTKs, BT474 and SKBR3 breast cancer cells were infected with recombinant retroviruses expressing either F-TrCP-Shc, F-TrCP-Shc(m) or the pBMN-GFP viral vector. Infected cells with chromosomally integrated chimeric F-TrCP transgenes were isolated by fluorescence-activated cell sorting (FACS) based on the expression of GFP from the viral vector. The endogenous expression levels of ErbB RTKs (overall protein levels including the tyrosine phosphorylated/ activated subpopulations) in BT474 and SKBR3 cells were determined by western blotting (Figures 2a and b , lane 1). We note that three ErbB proteins, EGFR, ErbB2 and ErbB3, are expressed in BT474 and SKBR3 cells and the activated subpopulations of these ErbB RTKs can be detected using their respective phospho-specific antibodies (Figures 2a and b , lane 1). However, ErbB4 expression cannot be detected in BT474 or SKBR3 cells (data not shown), as documented previously. 29 As shown in Figures 2a and b, the constitutive expression of F-TrCP-Shc selectively degraded tyrosine-phosphorylated ErbB2 in both SKBR3 and BT474 cells, whereas the overall ErbB2 expression levels, consisting predominantly of unmodified and inactive ErbB2, were largely unaffected. Furthermore, F-TrCP-Shc also selectively depleted the activated pools of EGFR and ErbB3 without compromising their overall levels of expression (Figures 2a and b, lane 2). In contrast, F-TrCP-Shc(m), which is unable to interact with ErbB RTKs, had no effect on their steady-state levels ( Figures 2a and b, lane 3) . The mRNA levels of EGFR, ErbB2 and ErbB3 in these cell lines were not altered significantly by the ectopic expression of F-TrCP-Shc or F-TrCP-Shc(m) (Supplementary Figure S2 ). Taken together with the rescue of F-TrCP-Shc-induced ErbB2 degradation by the proteasome inhibitor MG132 (Figure 1e ), we conclude that the engineered F-TrCP-Shc ubiquitin ligase operates at the posttranslational level to specifically ubiquitinate and degrade the entire family of activated ErbB RTKs.
Ubiquitination of membrane receptors accelerates endocytosis, resulting in an overall reduction in cell surface levels. 28, 30, 31 In order to determine whether F-TrCP-Shc-induced receptor and references therein). Therefore, we next chose to examine whether targeting the ErbB family of proteins with our E3 ligase had an effect on these crucial oncogenic signaling pathways. As seen in Figures 3a and 4a , the attenuation of ErbB signaling by targeted proteolysis was accompanied by the diminished phosphorylation (and activation) of AKT and MAPK. Thus, F-TrCP-Shc inhibited both signaling pathways in BT474 and SKBR3 cells, whereas the overall levels of AKT and MAPK were not affected (Figures 3a and 4a) . In contrast, the constitutive expression of the binding-deficient F-TrCP-Shc(m) did not alter phospho-AKT or phospho-MAPK levels and signaling, as compared with the control pBMN-GFP-infected BT474 and SKBR3 cells (Figures 3a and 4a) . Therefore, the targeted depletion of ErbB RTKs effectively attenuates the downstream MAPK and PI3K/AKT signaling cascade.
Cell cycle inhibition and increased apoptosis occur upon depletion of ErbB RTK in breast cancer cells The ErbB receptor family members stimulate cell proliferation and promote the survival of breast cancer as well as other tumor types. Thus, we next examined whether the targeted degradation of all activated ErbB RTKs inhibits the growth and survival of BT474 and SKBR3 cells. As shown in Figures 3b and 4b , the ectopic expression of F-TrCP-Shc led to a marked reduction of the growth rates of We further determined the cell cycle profiles of SKBR3 cells infected with pBMN-F-TrCP-Shc, pBMN-F-TrCP-Shc(m) or pBMN-GFP retroviruses by measuring 5-bromo-2-deoxyuridine (BrdU) incorporation via FACS analysis. As shown in Figure 3c Furthermore, the targeted degradation of ErbB RTKs induced approximately three-to fourfold increase in apoptosis, as determined by Annexin V/7-AAD staining and FACS analysis (Figure 3e ), as well as increased cleavage of poly(ADP-ribose) polymerase (Figure 3f) . Therefore, the inhibition of cell cycle progression and induction of apoptosis by F-TrCP-Shc both contribute to its growth suppressive effect on ErbB2-overexpressing SKBR3 cells.
In BT474 cells, the enforced expression of F-TrCP-Shc led to a modest inhibition of cell cycle progression, as indicated by the approximately 10-14% reduction of S phase populations compared with controls, and a concomitant increase in G1 and G2/M populations (Supplementary Figure S3) . However, the most striking effect of F-TrCP-Shc in BT474 cells is the robust induction of apoptosis. As measured by Annexin V and 7-AAD staining and FACS analysis, early apoptosis was increased 14-fold in F-TrCP-Shcexpressing cells compared with pBMN-GFP cells (11.7% versus 0.83%), whereas F-TrCP-Shc(m) did not induce apoptosis (0.79%; Figure 4c ). Furthermore, increased poly(ADP-ribose) polymerase cleavage was detected in BT474 cells stably expressing F-TrCP-Shc (Figure 4d ). These results indicate that the downregulation of Targeted depletion of ErbB RTKs had no discernable effect on non-cancerous MCF-10A mammary epithelial cells We next sought to determine whether non-cancerous mammary epithelial cells are also subjected to F-TrCP-Shc-mediated growth inhibition or whether ErbB-overexpressing breast cancers are particularly sensitive to the engineered ligase. Non-cancerous MCF-10A mammary epithelial cells were infected with the pBMN-F-TrCP-Shc, pBMN-F-TrCP-Shc(m) or pBMN-GFP retroviruses. Reduction of endogenous ErbB2 levels was observed, similar to that observed in SKBR3 and BR474 cells (Figure 5a) . Strikingly, the depletion of endogenous ErbB RTKs by pBMN-F-TrCP-Shc had little impact on the growth rate of MCF-10A cells, similar to those infected with pBMN-F-TrCP-Shc(m) or pBMN-GFP (Figure 5b ). Cell cycle arrest or apoptotic induction was not observed in MCF-10A cells stably expressing F-TrCP-Shc (Figures 5c and d) . It is noteworthy that while epidermal growth factor (EGF) stimulates the proliferation rate of MCF10A, 35, 36 ErbB-knockdown by F-TrCPShc was carried out under normal culture conditions in the absence of exogenous EGF. This non-exponential growth of MCF10A cells is likely less dependent on EGF signaling. Therefore, the engineered F-TrCP-Shc ligase specifically inhibits the proliferation of ErbB-overexpressing breast cancer cells, but exerts little effect on non-stimulated mammary epithelial cells. These results indicate that the simultaneous family-wide targeting of activated ErbB RTKs is a feasible intervention strategy for breast cancer.
F-TrCP-Shc sensitizes SKBR3 and BT474 cells to cisplatin and inhibits tumorigenicity in vitro and in vivo Several retrospective studies have suggested that ErbB2 overexpression is associated with a reduced efficacy of adjuvant chemotherapy.
37,38 Therefore, we hypothesized that F-TrCP-Shc would render breast cancer cells more susceptible to chemotherapy agents. BT474 cells expressing F-TrCP-Shc or F-TrCP-Shc(m) were treated with doses of cisplatin ranging from 12.5 to 100 mM, and cell viability was measured 48 h after treatment. As shown in Figure 6a , F-TrCP-Shc reduced the viability of BT474 cells upon cisplatin treatment. For example, at 37.5 mM, the number of viable cells is approximately 30% lower than control BT474 cells infected with pBMN-GFP or pBMN-F-TrCP-Shc(m) (Figure 6a) . A similar result was observed in BT474 cells (data not shown). In contrast, MCF-10A cells expressing F-TrCP-Shc did not display enhanced cytotoxicity in response to cisplatin compared with those expressing F-TrCP-Shc(m) or pBMN-GFP ( Figure 6b) .
Next, we assessed the oncogenic potential of F-TrCP-Shcexpressing breast cancer cells by focus formation assays. Retrovirally expressed F-TrCP-Shc caused a 50% reduction in focus (Figure 7) . At week 3, the average tumor weight of F-TrCP-Shc-expressing BT474 xenografts was 50% less than pBMN-GFP-and F-TrCP-Shc(m)-expressing BT474 xenografts (Po0.01 and Po0.05, respectively; Figure 7b ). Collectively, these data indicate that the targeted degradation of activated ErbB family proteins significantly reduced the oncogenic potential of ErbB2-overexpressing breast cancer cells, and sensitized those cells to the cisplatin chemotherapeutic agent.
DISCUSSION
Given the extensive crosstalk among the ErbB RTKs, it is plausible that blocking signaling from more than one family member may be necessary to effectively eradicate tumors and limit the occurrence of drug resistance. Currently, there are no effective tools or reagents available that can simultaneously abrogate the functions of all ErbB RTKs, and no studies have evaluated whether broad ErbB RTK inactivation preferentially kills tumor versus normal cells. Moreover, although the complete eradication of ErbB RTK expression is highly toxic to all cells, selectively targeting the active, tyrosine-phosphorylated forms of ErbB RTKs may be an effective strategy to preferentially kill tumor cells. However, more refined tools are required to achieve this delicate selection.
Targeting proteins for ubiquitination and subsequent proteasomal degradation is the primary mode of regulating the abundance of cellular proteins on the posttranscriptional level. Here, we showed that fusion of the Shc PTB domain to the bTrCP ubiquitin ligase allows for the selective recruitment of the activated subpopulations of the ErbB family of RTKs to the SCF machinery for ubiquitination and proteasome-dependent degradation, and effectively attenuates MAPK and PI3K signaling. Simultaneous degradation of all activated ErbB RTKs exerts dramatic cytotoxic effects on ErbB2-overexpressing breast cancer cells by inducing robust growth inhibition and apoptosis, and enhancing sensitivity to the chemotherapy drug cisplatin (Figures 4 and 5) . Our findings are in sharp contrast to ErbB tyrosine kinase inhibitors that primarily induce cytostatic attenuation of tumor growth. 29 Major inroads for targeted therapy against ErbB2-positive breast cancers were achieved with the development of trastuzumab, a monoclonal antibody that targets the extracellular domain of ErbB2. However, a majority of patients with advanced disease, as well as a proportion of those receiving treatment for operable disease, experience metastatic progression within 1 year of treatment because of the development of resistance to trastuzumab. [39] [40] [41] One such mechanism of resistance is the compensatory upregulation of other ErbB RTKs, for example, ErbB3, which effectively restores ErbB signaling through the PI3K/Akt axis of signaling and promotes the survival of tumor cells despite the continued presence of trastuzumab. 29, 42 Moreover, ErbB3 lacks a kinase domain that renders it refractory to smallmolecule inhibitors. Our F-TrCP-Shc construct addresses this particular concern by successfully targeting activated ErbB3 for proteasomal degradation (Figures 2a and b) .
Our engineered F-TrCP-Shc construct has the unique capability of selectively recruiting the active forms of all ErbB RTKs for degradation (Figure 2 ). This unique property allows for the specific targeting of the oncogenic forms of ErbB RTKs while leaving the native forms intact. Strikingly, F-TrCP-Shc induced apoptosis, increased cisplatin sensitivity and reduced the tumorigenicity of 5) . A somewhat surprising yet encouraging observation is that other cellular proteins that can interact with the Shc PTB domain and are theoretically also subjected to ubiquitindependent degradation by F-TrCP-Shc, such as c-Met, were not degraded in ErbB2-overexpressing BT474 cells (Supplementary Figure S4) . This finding suggests that the engineered ubiquitin ligase preferentially engages with the active forms of Shc-binding partners (that is, the ErbB RTKs). Collectively, our studies suggest that the perceived adverse effects upon the eradication of all ErbB RTKs can be mitigated by designing agents that target the activated subpopulations of ErbBs, thereby achieving the optimal tumoricidal outcome while minimizing the therapy-associated cytotoxic side-effects to normal cells. The goal of the present study is to test the engineered ubiquitin ligase strategy for simulating the consequences of pharmacological eradication of the entire family of activated ErbB RTKs in ErbB-overexpressing tumor cells, and further assess the impact on non-malignant mammary epithelial cells. Compared with gene knockout approaches to assess the outcomes of ErbB RTK ablation, the engineered F-TrCP-Shc ubiquitin ligase is anticipated to more closely recapitulate the actions of pharmaceutical agents. It reduces but does not completely eliminate its intended targets, and therefore may not elicit the same severity of consequences as those that could arise from gene knockout. Moreover, the unique properties of the protein knockout system in interrogating complex protein functions, including posttranslational modifications, subcellular distributions and functional redundancy, offer a versatile and powerful investigative tool for the rapid assessment of specific traits in tumorigenesis, maintenance and resistance to therapy, and inform new and improved therapeutic modalities against human malignancy. Future studies should directly compare the therapeutic effects of eradicating a single or multiple ErbB family members in pre-clinical models, and evaluate the potential of pan-ErbB suppression as a feasible strategy for the development of the next generation of targeted therapies against ErbB-positive tumors. The engineered ubiquitin ligase system developed here should be widely applicable to the assessment of protein families or specific posttranslational modifications as potential new targets for therapeutic intervention.
MATERIALS AND METHODS

Cell lines, antibodies and reagents
Human mammary carcinoma cell lines SKBR3 and BT474, and noncancerous MCF-10A mammary epithelial cells were obtained from American Type Culture Collection. Antibodies against b-actin, EGFR (1005), ErbB2(C-18), cyclin D1 (M-20) and p27 (C-19) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Akt, p-Akt (Ser473), p38MAPK, p-MAPK, p-EGFR (Y1148), p-ErbB2 (Y1248), ErbB3 and p-ErbB3 (pY1328) from Cell Signaling (Andover, MA, USA). Anti-ErbB2 antibodies used for immunofluorescence and FACS analysis were purchased from R&D Systems (Minneapolis, MN, USA) and Santa Cruz, respectively. SYBR Green universal master mix and Multiscript RT were purchased from Applied Biosystems (Foster City, CA, USA). Cisplatin from Enzo Life Sciences (Plymouth Meeting, PA, USA), and the proteasome inhibitor MG132 and lysosomal inhibitor chloroquine from Calbiochem (Billerica, MA, USA).
Plasmid construction, transfection and retroviral infection
The PTB domain (1-209 aa) and mutant PTB(F198V) from Shc were fused to carboxyl terminus of FLAG-tagged bTrCP, and the resulting F-TrCP-Shc and F-TrCP-Shc(F198V) were subcloned into the BamHI/NotI sites of the retroviral pBMN-GFP vector to generate recombinant retroviruses 43 for infection of SKBR3, BT474 and MCF10A cells, as detailed in Chen et al. 44 FACS analysis was carried out to isolate infected cells, which was based on the expression of GFP from the recombinant retroviruses. Immunoprecipitation and western blot analysis were carried out as described. 45 F-TrCP-Shc was also subcloned into the pAdTrack-CMV adenoviral vector to generate recombinant adenoviruses for infection of SKBR3 cells. 46 Flow cytometry analysis of cell membrane-localized ErbB2
Flow cytometric analysis of cell membrane-localized ErbB2 was performed on live SKBR3 cells. Briefly, SKBR3 cells infected with pBMN-F-TrCP-Shc, pBMN-F-TrCP-Shc(m) or pBMN-GFP retroviruses were trypsinized, washed in ice-cold FACS buffer (2% fetal bovine serum, 2% bovine serum albumin in phosphate-buffered saline containing 0.02% sodium azide) and serially stained with primary (anti-ErbB2) and secondary APC-conjugated anti-goat IgG antibodies (R&D Systems, Minneapolis, MN, USA) on ice in the same buffer. Stained cells were analyzed using the BD LSR II flow cytometer (BD Biosciences, San Jose, CA, USA).
Cell cycle, cell proliferation, apoptosis and focus formation assays Targeting all activated ErbBs by protein knockout F Kong et al with phosphate-buffered saline containing 10 mg/ml propidium iodide. Cell proliferation rate was determined by plating 2 Â 10 4 cells and counting at the indicated time points (Figures 3b, 4b and 5d ) using an automated cell counter (Invitrogen, Grand Island, NY, USA). Each experiment was carried out in triplicate and repeated twice. The results are expressed as the mean ± s.d. for each set of experiments. Apoptosis was measured by Annexin V-APC and 7-AAD staining and flow cytometry using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences). To measure focus formation, 3.0 Â 10 3 SKBR3 cells or 6.0 Â 10 3 BT474 cells were seeded in six-well plates for 10 days, stained with 0.2% crystal violet and foci were counted. Images of the colonies were obtained using a NIKON digital camera (Nikon Inc., Melville, NY, USA).
In vitro drug sensitivity assay 
Statistical analysis
Statistical analysis was performed with the SPSS15.0 software package for Windows by using the Student's t-test for independent groups. Statistical significance was based on a value of Pp0.05. Data are expressed as mean±s.d.
